ARGC Arion Group Corporation (CE)

Artepharm Global Corp. (the "Company") (OTCBB: ARGC) July 13, 2010. The World Health Organisation reports that half of the world's population is at risk of Malaria, and an estimated 243 million cases led to nearly 863 000 deaths in 2008.

The renewed effort to control malaria worldwide and move towards elimination in some countries is founded on the latest generation of effective tools and methods for prevention and treatment. Increasing use of long-lasting insecticide nets (LLINs), artemisinin-based combination therapies (ACTs) and indoor residual spraying (IRS) of insecticide provides an unprecedented opportunity to control and, in selected countries, eliminate malaria.

Artepharm is global leader in Artemisinin-Based Combination Therapy

Artepharm Global's leading products include the artemisinin-based combinations: the Artequick® tablet, Artequick® granules and Artemisinin raw products.

Artequick has numerous outstanding advantages, both in efficacy, course of treatment, toxicity, and convenience in usage and diversity in dosage forms. Compared to similar products, Artequick is very low-cost, has low toxicity, and is easy-to-administer with a short course of six pills. There is also an easy-to-administer children's granular formula. The most significant advantage is the low product cost as the majority of malaria patients are typically poor.

Artepharm to Eradicate Malaria in Comoros Islands, East Africa

The Comoros Islands are a small chain of islands in East Africa (population 800,000) in which 28% of the residents are infected with Malaria. In 2007 Artepharm with its patented ArteQuick Malaria treatment reduced the Malaria rate on the Comoros Island of Moheli from over 20% of the population to less than 1%. Strict Procedural controls will be deployed with this upcoming trial on the rest of the Comoros Islands with the intent of attracting support from the World Health Organisation to back ArteQuick has the leading Global treatment for Malaria.

See Dateline News Video of Artepharm's success in Moheli on the Company's web site www.artepharmglobal.com.

About Artepharm Global

Artepharm Global has acquired the patent and worldwide marketing rights for Artequick®, a natural artemisinin-based anti-malaria drug developed by Artepharm Co. Artepharm Co. is a modern pharmaceutical company involved in R&D and the manufacturing of artemisinin-based anti-malarias and anti-viral traditional Chinese medicines. It was jointly established by a group of experts specializing in the research of Qinghao, commonly known as Artemisia annua. For more information got to www.artepharmglobal.com.

Safe Harbour Statements

Except for the statements of historical fact contained herein, the information presented in this news release constitutes "forward-looking statements" as such term is used in applicable United States and Canadian laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans, "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and should be viewed as "forward-looking statements". Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the actual results of exploration activities, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labour disputes and other risks of the mining industry including, without limitation, those associated with the environment, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, title disputes or claims limitations on insurance coverage. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.

Forward looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. Such forward-looking statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, including, the risks and uncertainties outlined in our most recent financial statements and reports and registration statement filed with the United States Securities and Exchange Commission (the "SEC") (available at www.sec.gov) and with Canadian securities administrators (available at www.sedar.com). Such risks and uncertainties may include, but are not limited to, the risks and uncertainties set forth in the Company's filings with the SEC, such as the ability to obtain additional financing, the effect of economic and business conditions, the ability to attract and retain skilled personnel and factors outside the control of the Company. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the SEC. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities of the Company nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Contacts: Artepharm Global Corp. (604) 575-3552 www.artepharmglobal.com